Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
AMRNNegative Net Change ANIPNegative Net Change BHCNegative Net Change AMRXNegative Net Change
earnings medical pharmaceuticals
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
LGNDNegative Net Change ZTSPositive Net Change BPMCNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
UTHRNegative Net Change LGNDNegative Net Change CORTNegative Net Change ANIPNegative Net Change
pharmaceuticals
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
MRKNegative Net Change MRNAPositive Net Change LGNDNegative Net Change ANIPNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYPositive Net Change LGNDNegative Net Change SRPTPositive Net Change ANIPNegative Net Change
biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GSKNegative Net Change BMYNegative Net Change GILDPositive Net Change EDITNegative Net Change DCPHNo Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change TSVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
NVONegative Net Change LGNDNegative Net Change BPMCNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
PPLPositive Net Change ADPPositive Net Change PFEPositive Net Change CVSPositive Net Change
business-services pharmaceuticals utilities
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
PFEPositive Net Change LGNDNegative Net Change ANIPNegative Net Change BNTXPositive Net Change
pharmaceuticals
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSKNegative Net Change JNJPositive Net Change ANIPNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
LLYNegative Net Change XLVNegative Net Change IYHNegative Net Change IHENegative Net Change PPHNegative Net Change MEDXNegative Net Change
earnings etfs pharmaceuticals
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
ALNYPositive Net Change ATRANegative Net Change ARGXNegative Net Change ANNXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
EXELPositive Net Change AMRNNegative Net Change ANIPNegative Net Change VYGRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 1, 2024
by Zacks Equity Research
Companies In The News Are: PYPL, LLY, MMM, GLW.
LLYNegative Net Change MMMPositive Net Change GLWPositive Net Change PYPLPositive Net Change
communications internet multi-sector-conglomerates pharmaceuticals
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
KOPositive Net Change LLYNegative Net Change ETNNegative Net Change
consumer-staples pharmaceuticals utilities
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
NVONegative Net Change LLYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change
pharmaceuticals
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNNegative Net Change PFEPositive Net Change NVONegative Net Change AMGNNegative Net Change MRNAPositive Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AMZNNegative Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXNegative Net Change MCDNegative Net Change SMCINegative Net Change
consumer-staples multi-sector-conglomerates pharmaceuticals restaurants
Pre-Markets Sell on Last Trading Day of April
by Mark Vickery
Today we close out a month that's likely to be the first negative one since October of last year.
AMZNNegative Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXNegative Net Change MCDNegative Net Change SMCINegative Net Change
consumer-discretionary earnings industrial-products pharmaceuticals
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ALNYPositive Net Change VRTXPositive Net Change CRSPNegative Net Change ALPNNegative Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change SRPTPositive Net Change ARGXNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRNegative Net Change EXELPositive Net Change SRPTPositive Net Change COLLNegative Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYPositive Net Change SRPTPositive Net Change ARGXNegative Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals